Key Highlights
• RadNet reported Q2 2026 Revenue of $622.7 million, up 25 percent year-over-year, and adjusted EBITDA of $99.7 million, up 22.7 percent, both quarterly records.
• Digital Health annual Recurring Revenue reached $105.5 million, up 97 percent year-over-year, with a full-year target of over $140 million.
• The company raised full-year 2026 imaging center guidance for revenue, adjusted EBITDA, and free Cash Flow .
• RadNet received FDA 510(k) clearance for its DeepHealth breast ultrasound AI solution, covering nearly 1 million annual studies once fully deployed.
Imaging Center Growth Driven by Advanced Imaging and Health System Partnerships
RadNet, Inc. ( Nasdaq :RDNT) reported total company revenue of $622.7 million for the second quarter, up 25 percent from $498.2 million a year earlier, with adjusted EBITDA rising 22.7 percent to $99.7 million. RadNet operates a network of 442 outpatient imaging centers across the United States alongside a Digital Health segment developing AI and enterprise imaging software. Aggregate advanced imaging procedural volumes, spanning MRI, CT, and PET CT, increased 21.2 percent, while same-center advanced imaging volumes rose 9.6 percent, aided by faster MRI scanners and remote technologist coverage that has helped address ongoing staffing shortages.
Health system joint ventures continued to expand, with 157 of the company's 442 centers, or approximately 36 percent, now held within such partnerships, including a new multi-site venture in Boise, Idaho announced during the quarter. Imaging center segment adjusted EBITDA Margin improved 17 basis points to 16.1 percent, a gain management attributed to the favorable shift toward advanced imaging and continued cost discipline, even as salary pressure on technologists and radiologists persisted.
Digital Health Segment Nearly Doubles Annual Recurring Revenue
RadNet's Digital Health segment generated $32.4 million in revenue, up 56.5 percent year-over-year, split between AI revenue of $16.1 million, up 136 percent, and enterprise imaging revenue of $16.3 million, up 17.3 percent. Annual recurring revenue reached $105.5 million, up 97 percent year-over-year, and the company remains on track to reach approximately $140 million in ARR by year-end, supported by a clinical AI and enterprise imaging sales funnel that has grown from roughly $101 million to more than $224 million since the start of the year.
Segment profitability has not kept pace with revenue growth. Digital Health adjusted EBITDA was $2.5 million for the quarter, down from $3.4 million a year earlier, reflecting deliberate Investment in commercial and implementation headcount alongside temporary margin dilution from recent acquisitions, including Gleamer. Management maintained its full-year segment guidance of $135 million to $145 million in revenue and $10 million to $12 million in adjusted EBITDA, implying a steep ramp in profitability over the remainder of the year that has yet to materialize in reported results.
Breast Ultrasound AI Clearance Expands Draft Reporting Coverage
RadNet received FDA 510(k) clearance for its DeepHealth breast ultrasound AI solution, which automates lesion detection and generates standardized draft reports, and demonstrated greater than 98 percent accuracy in localizing breast lesions during validation studies along with a 37 percent reduction in radiologist interpretation time. The company plans to deploy the tool across its network by year-end, covering nearly 1 million annual breast ultrasound studies, roughly four times the Volume of its existing thyroid ultrasound AI application.
Reimbursement remains an open variable. The solution is eligible for billing under an existing Category III CPT code, the same code used for the company's thyroid ultrasound product, and management expects payer coverage to ramp faster than it did for thyroid given established payer determinations, though it will still take time to reach the 30 to 40 percent payer coverage level the company has achieved for thyroid ultrasound over a longer rollout period.
Conclusion
RadNet's second quarter combined record imaging center financial performance with continued rapid scaling of its Digital Health ARR base, prompting a guidance increase across imaging center revenue, adjusted EBITDA, and free cash flow. The breast ultrasound FDA clearance extends the company's draft-reporting AI strategy into a substantially larger exam volume than its earlier thyroid application, though the pace of reimbursement and full network rollout will likely determine how quickly that opportunity converts into segment profitability. Continued technologist staffing pressure and a proposed Medicare site-neutrality provision affecting hospital radiology reimbursement remain factors that could influence both cost structure and health system Partnership Demand into 2027.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...